TransMedics Group, Inc. (NASDAQ:TMDX) Given Average Recommendation of "Moderate Buy" by Analysts

TransMedics Group, Inc. (NASDAQ:TMDX - Get Free Report) has earned a consensus rating of "Moderate Buy" from the eleven ratings firms that are covering the firm, Marketbeat Ratings reports. Three analysts have rated the stock with a hold recommendation, seven have issued a buy recommendation and one has given a strong buy recommendation to the company. The average 12-month target price among brokers that have issued a report on the stock in the last year is $122.70.

A number of brokerages have recently issued reports on TMDX. Canaccord Genuity Group reissued a "buy" rating and issued a $104.00 price objective on shares of TransMedics Group in a research note on Tuesday, March 11th. Needham & Company LLC reiterated a "hold" rating on shares of TransMedics Group in a research note on Wednesday, March 26th. JPMorgan Chase & Co. reissued a "neutral" rating and set a $75.00 price target (down from $116.00) on shares of TransMedics Group in a report on Tuesday, December 17th. Robert W. Baird dropped their price objective on TransMedics Group from $150.00 to $120.00 and set an "outperform" rating for the company in a research note on Wednesday, December 11th. Finally, Piper Sandler decreased their target price on TransMedics Group from $110.00 to $90.00 and set an "overweight" rating on the stock in a research note on Wednesday, December 11th.

TransMedics Group Stock Performance

TransMedics Group stock traded down $3.29 during midday trading on Thursday, hitting $67.67. The stock had a trading volume of 1,381,312 shares, compared to its average volume of 1,323,267. TransMedics Group has a 52-week low of $55.00 and a 52-week high of $177.37. The company has a market capitalization of $2.28 billion, a PE ratio of 71.99 and a beta of 2.14. The firm's fifty day moving average is $69.93 and its two-hundred day moving average is $86.32. The company has a current ratio of 8.20, a quick ratio of 7.33 and a debt-to-equity ratio of 2.42.

Remove Ads

Institutional Trading of TransMedics Group

Several hedge funds have recently modified their holdings of the company. Vanguard Group Inc. increased its position in TransMedics Group by 1.1% in the fourth quarter. Vanguard Group Inc. now owns 3,635,919 shares of the company's stock worth $226,700,000 after purchasing an additional 40,860 shares during the last quarter. FIL Ltd increased its holdings in shares of TransMedics Group by 28.0% in the 4th quarter. FIL Ltd now owns 1,000,358 shares of the company's stock worth $62,372,000 after buying an additional 218,961 shares during the last quarter. Braidwell LP purchased a new stake in shares of TransMedics Group during the 4th quarter valued at about $57,493,000. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC raised its position in shares of TransMedics Group by 16.6% during the 4th quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 903,086 shares of the company's stock valued at $56,307,000 after buying an additional 128,474 shares in the last quarter. Finally, Mackenzie Financial Corp lifted its holdings in shares of TransMedics Group by 73.0% in the 4th quarter. Mackenzie Financial Corp now owns 828,147 shares of the company's stock valued at $51,635,000 after acquiring an additional 349,403 shares during the last quarter. 99.67% of the stock is owned by hedge funds and other institutional investors.

TransMedics Group Company Profile

TransMedics Group, Inc, a commercial-stage medical technology company, engages in transforming organ transplant therapy for end-stage organ failure patients in the United States and internationally. The company offers Organ Care System (OCS), a portable organ perfusion, optimization, and monitoring system that utilizes its proprietary and customized technology to replicate near-physiologic conditions for donor organs outside of the human body.